Get the Stockscreener App
1.62
0.62%
0.01
After Hours:
1.60
-0.02
-1.23%
Opko Health Inc stock is traded at $1.62, with a volume of 2.52M.
It is up +0.62% in the last 24 hours and down -0.61% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.61
Open:
$1.6
24h Volume:
2.52M
Relative Volume:
0.28
Market Cap:
$1.21B
Revenue:
$581.12M
Net Income/Loss:
$-212.92M
P/E Ratio:
-5.9167
EPS:
-0.2738
Net Cash Flow:
$-174.22M
1W Performance:
+1.25%
1M Performance:
-0.61%
6M Performance:
+33.88%
1Y Performance:
+12.50%
1-Day Range:
$1.59
$1.655
1-Week Range:
$1.59
$1.67
52-Week Range:
$0.9769
$1.77
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, NTRA, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.62 | 1.21B | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
704.15 | 260.36B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
234.07 | 164.55B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
424.27 | 61.16B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
181.48 | 51.16B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
476.88 | 46.85B | 3.77B | 449.25M | 240.68M | 7.8556 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-26 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Apr-29-26 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-20-25 | Initiated | JP Morgan | Neutral |
| Oct-31-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
OPKO Health to Report Third Quarter 2026 Financial Results on November 4 - Quiver Quantitative
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 - The Manila Times
Ecolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/Y - Zacks Investment Research
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Reports First Patient Dosed in Phase 1/2a Trial in Acromegaly - marketscreener.com
OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly - Yahoo! Finance Canada
Enterprise value to EBIT forward of OPKO Health, Inc. – LS:A0MUUJ - TradingView
OPKO Health, Inc. (OPK) Options Chain - Yahoo! Finance Canada
OPKO Health, Inc. expected to post a loss of 7 cents a shareEarnings Preview - TradingView
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy - Zacks Investment Research
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI - Zacks Investment Research
Opko Health, Inc. Estimates – NASDAQ:OPK - TradingView
GEHC Expands Theranostics Imaging With 5 Global Collaborations - Zacks Investment Research
Revvity Launches Signals LabGistics to Coordinate Scientific Workflows - Zacks Investment Research
3 Promising Penny Stocks With Over $200M Market Cap - Simply Wall Street
Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp - PR Newswire
H.C. Wainwright keeps USD 3.00 target for OPKO Health stock - AD HOC NEWS
OPKO Health (OPK) Sells BioReference Assets On A Valuation Story That Still Divides - Yahoo Finance
Barrington sets USD 2.25 target for OPKO Health stock - ad-hoc-news.de
Is OPKO Health (OPK) Pricing In Too Much For Sales? - Yahoo Finance
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - Zacks Investment Research
Opko Health Inc. (OPK) Stock Price | Live Quotes & Charts | NASDAQ - Timothy Sykes
Piper Sandler raises Opko Health stock price target on LabCorp deal - Investing.com
OPKO Health (NASDAQ:OPK) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - Zacks Investment Research
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - TradingView
Opko Health stock hits 52-week high at 1.75 USD By Investing.com - Investing.com Canada
Ladder Capital Posts Upbeat Q3 Earnings, Joins Alcoa, Hyster-Yale And Other Big Stocks Moving Higher On Friday - Benzinga
Opko Health stock hits 52-week high at 1.75 USD - Investing.com
H.C. Wainwright reiterates Opko Health stock rating on Labcorp deal By Investing.com - Investing.com Canada
OPKO HEALTH, INC. : BARRINGTON RESEARCH RAISES TO OUTPERFORM FROM MARKET PERFORM - Moomoo
OPKO Health (NASDAQ:OPK) Stock Rating Raised to Outperform at Barrington Research - MarketBeat
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - Yahoo Finance
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients - Zacks Investment Research
Why Is Opko Health Stock Gaining Thursday?OPKO Health (NASDAQ:OPK), Labcorp Holdings (NYSE:LH) - Benzinga
OPKO Health (NASDAQ:OPK) Shares Gap UpWhat's Next? - MarketBeat
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care - Zacks Investment Research
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday - Benzinga
OPK Stock Slides As Charts Flash Potential Pivot Zone - Timothy Sykes
Opko Health stock soars on $722M BioReference asset sale - Investing.com
OPK Stock Slides As Traders Weigh Weak Cash Flow And Support Levels - Timothy Sykes
Labcorp to buy select assets from Opko Health unit for up to $872 million - Reuters
OPK Stock Slips As Traders Weigh Weak Margins And Support Levels - StocksToTrade
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health - PR Newswire
A prostate cancer blood test may reach more patients if Labcorp completes its deal - Stock Titan
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? - Zacks Investment Research
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now - Zacks Investment Research
Hims & Hers Expands Australian Women's Health Platform With Hers - Zacks Investment Research
OPKO Health (NASDAQ:OPK) Share Price Breaks Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
6.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):